Gerresheimer AG GRRMY

Health CareHealthcare Equipment & SuppliesGermany

Last close 9.21 USD on Nov 1, 2026, +18.4% year to date

Quant rating

Quant rating B Rank 77 of 211 in Health Care

Growth A 13 of 211
Valuation B 50 of 211
Quality B 78 of 211
Revisions D 172 of 211
Momentum B 70 of 211

Wall Street consensus Hold (3.14)Average target 31.31 USD +239.9%

Historical valuation

Multiples use consensus estimates for the next twelve months. The dashed line is the 5-year average.

Key data

Market cap: 1.2B
Enterprise value: 3.5B
52-week range: 4.71 – 9.79
3-year range: 4.71 – 30.00
Dividend yield: 0.12%
Beta (5 years): –
Shares outstanding: 34.5M
Next earnings: Jul 15, 2026

About the company

Gerresheimer AG is a Germany-based company that is active in the pharmaceuticals and health care industry. It operates through two business segments: Plastics and Devices, and Primary Packaging Glass. The Plastics and Devices segment produces standard and customized products for drug delivery, such as insulin pens, inhalers, and prefillable syrings. The Primary Packaging Glass segment focuses on the production of packaging of glass for medicines and cosmetics, such as pharmaceuticals jars, ampoules, injection vials, cartridges, perfume flacons and cream jars, as well as glass containers for the food and beverage industry. The Company operates approximately 40 production facilities in Europe, North America, South America and Asia.

Growth and profitability

Growth and profitability by fiscal year
	2025	2024	2023	2022	2021	5Y avg
Revenue (mil)	2,691	2,106	2,167	1,891	1,698	–
Revenue growth	27.8%	−2.8%	14.6%	11.3%	0.3%	9.7%
EPS (basic, normalized)	−2.14	4.92	5.00	4.88	4.69	–
EPS growth	–	−1.7%	2.4%	4.1%	–	–
Gross margin	18.3%	28.5%	30.0%	30.1%	29.5%	27.3%
Net margin	−13.8%	4.1%	5.8%	5.3%	5.6%	1.4%
ROE	−25.0%	5.6%	8.6%	8.6%	8.9%	1.4%

Balance sheet, last quarter
Cash & short-term investments (mil)	219
Current ratio	1.07x
Long-term debt (mil)	1,875
Net debt (mil)	2,416
Total equity (mil)	1,130
Net debt / equity	2.14x
Net debt / EBITDA	5.51x

Estimates and valuation

Consensus estimates and implied multiples
	Sales (mil)			EBITDA (mil)			EPS
Fiscal year	Mean est.	Growth	EV/Sales	Mean est.	Growth	EV/EBITDA	Mean est.	Growth	P/E
2025 actual	2,691	+27.8%	1.3x	439	+1.2%	8.0x	−2.14	−143.4%	−4.3x
2026	2,584	−4.0%	1.4x	445	+1.5%	7.9x	2.10	+198.5%	4.4x
2027	2,583	0.0%	1.4x	462	+3.7%	7.6x	2.84	+35.1%	3.2x
2028	2,751	+6.5%	1.3x	498	+7.9%	7.1x	3.89	+36.9%	2.4x

Estimate revisions

Change in consensus estimates over 1, 3 and 6 months
	Sales				EPS
Fiscal year	Estimate (mil)	1M	3M	6M	Estimate	1M	3M	6M
2026	2,584	−1.0%	−1.1%	−2.2%	2.10	−11.0%	−21.1%	−23.7%
2027	2,583	−1.3%	−4.1%	−7.3%	2.84	−10.8%	−24.4%	−26.5%
2028	2,751	0.0%	−4.5%	−10.3%	3.89	0.0%	−17.3%	−19.3%

Earnings surprises EPS beat in 1 of the last 4 quarters

Reported results versus consensus, last 10 fiscal quarters
Quarter ended	Nov 2023	Feb 2024	May 2024	Aug 2024	Nov 2024	Feb 2025	May 2025	Aug 2025	Nov 2025	Feb 2026
Sales reported (mil)	545	466	502	498	569	520	601	561	640	475
Sales mean (mil)	542	460	502	500	567	523	600	567	614	514
Surprise	+0.5%	+1.2%	+0.1%	−0.3%	+0.3%	−0.6%	+0.1%	−1.1%	+4.2%	−7.6%
EPS reported	1.51	0.65	1.24	1.16	1.63	0.46	0.90	0.70	−4.44	−1.72
EPS mean	1.40	0.69	1.13	1.17	1.36	0.39	0.95	0.68	−2.06	−0.23
Surprise	+7.6%	−6.5%	+9.5%	−1.0%	+20.0%	+19.0%	−5.8%	+2.9%	−115.5%	−647.8%

Peer comparison Healthcare Equipment & Supplies

Peers in the same industry group, by market capitalization
Company	Market cap	Net debt/EBITDA	Net margin	P/B	FY1 P/E	FY2 P/E	FY1 EV/EBITDA	FY2 EV/EBITDA
GRRMY Gerresheimer AG	1.2B	5.51x	−13.8%	1.16x	4.4x	3.2x	7.9x	7.6x
TNDM Tandem Diabetes Care, Inc.	1.3B	−3.29x	−20.2%	10.19x	−28.0x	144.8x	27.2x	12.7x
CNMD Conmed Corp	1.3B	2.78x	3.4%	1.25x	9.7x	9.3x	7.4x	7.0x
STAA STAAR Surgical Company	1.2B	27.68x	−33.6%	3.37x	89.1x	44.4x	16.8x	13.7x
ENOV Enovis Corporation	1.1B	3.16x	−52.6%	0.78x	5.5x	5.5x	5.7x	5.5x
CSTL Castle Biosciences, Inc.	1.1B	−5.83x	−7.0%	2.41x	−29.2x	−37.2x	74.1x	36.2x
Mean		5.00x	−20.6%	3.19x	8.6x	28.4x	23.2x	13.8x
Median		2.97x	−17.0%	1.83x	4.9x	7.4x	12.4x	10.2x

Technical analysis

1M+11.0%
3M+16.6%
1Y+8.3%
3Y−63.2%

Financial statements in millions of USD

Income statement in millions of USD, fiscal years

Income statement, Gerresheimer AG, fiscal years, most recent first
	2025	2024	2023	2022	2021	2020
Total revenue	2,691	2,106	2,167	1,891	1,698	1,692
Cost of revenue	2,198	1,505	1,517	1,322	1,197	1,170
Gross profit	493	601	650	569	501	522
Selling, general & administrative expenses	443	363	355	315	280	278
Research & development	93.9	25.1	17.6	22.5	11.3	9.1
Depreciation/amortization	66.7	48.3	50.7	48.6	45.1	50.2
Interest expense (income), operating	4.4	1.5	1.7	0.5	0.7	1.5
Unusual expense (income)	141	12.9	9.8	18.6	9.4	13.2
Other operating expenses	−13.3	−20.0	−17.3	−12.0	−12.5	−17.1
Operating income	−243	170	232	176	167	187
Net interest income (expense)	−109	−58.9	−50.8	−27.0	−22.0	−23.0
Gain (loss) on sale of assets	–	–	–	–	–	–
Other non-operating income (expense)	−31.0	5.4	0.7	−2.6	−0.2	−2.4
Net income before taxes	−383	117	182	147	145	161
Provision for taxes	−13.2	27.5	51.5	40.2	46.1	54.0
Minority interest	−1.8	−2.2	−4.3	−6.3	−3.9	−1.6
Equity in affiliates	–	–	–	–	–	–
U.S. GAAP adjustment	–	–	–	–	–	–
Net income before extraordinary items	−371	87.0	126	100	95.0	106
Extraordinary items	–	–	–	–	–	–
Net income	−371	87.0	126	100	95.0	106
EBIT, normalized	118	190	247	195	178	201
EBITDA, normalized	448	400	446	373	342	384
Basic EPS, normalized	−2.14	4.92	5.00	4.88	4.69	–

Balance sheet in millions of USD, fiscal years

Balance sheet, Gerresheimer AG, fiscal years, most recent first
	2025	2024	2023	2022	2021	2020
Assets
Cash & short-term investments	204	197	133	117	129	105
Receivables	496	396	394	359	313	312
Total inventory	522	382	358	323	270	227
Prepaid expenses	9.2	6.7	5.6	6.2	5.2	6.0
Other current assets	46.3	33.0	34.3	36.7	27.8	7.8
Total current assets	1,279	1,015	925	843	745	658
Property, plant & equipment	2,153	1,591	1,381	1,104	1,025	910
Goodwill	1,010	715	729	713	744	766
Intangibles	700	592	645	658	717	754
Long-term investments	21.7	46.7	28.2	25.7	9.7	10.8
Note receivable	1.8	4.3	4.3	1.9	1.8	1.9
Other long-term assets	44.7	24.9	19.7	145	19.3	20.3
Total assets	5,210	3,990	3,733	3,490	3,262	3,121
Liabilities
Accounts payable	495	391	422	371	322	252
Payable/accrued	–	–	–	–	–	–
Accrued expenses	132	115	119	124	117	119
Short-term debt	0	0	0	0	0	0
Current portion of long-term debt	665	387	417	557	497	251
Other current liabilities	286	157	85.1	93.6	68.3	67.0
Total current liabilities	1,578	1,050	1,043	1,146	1,004	689
Long-term debt	1,855	969	717	713	788	999
Minority interest	30.0	28.6	29.1	27.5	23.7	18.9
Other liabilities	493	379	370	310	319	359
Total liabilities	3,956	2,427	2,159	2,197	2,135	2,067
Shareholders' equity
Preferred stock	–	–	–	–	–	–
Common stock	40.0	36.5	37.6	32.7	35.6	37.5
Additional paid-in capital	311	823	847	535	582	613
Retained earnings (accumulated deficit)	1,052	754	742	639	611	565
Treasury stock	–	–	–	–	–	–
Other equity	−149	−51.0	−52.8	86.6	−102	−161
Total equity	1,254	1,563	1,574	1,293	1,127	1,054
Total liabilities & shareholders' equity	5,210	3,990	3,733	3,490	3,262	3,121

Cash flow statement in millions of USD, fiscal years

Cash flow statement, Gerresheimer AG, fiscal years, most recent first
	2025	2024	2023	2022	2021	2020
Operating activities
Net income	−370	89.2	131	106	98.9	107
Depreciation, depletion & amortization	606	215	203	179	165	174
Deferred taxes	–	–	–	–	–	–
Non-cash items	134	33.2	63.9	50.8	37.6	69.3
Changes in working capital	−127	−85.0	−76.7	−105	−60.8	−85.1
Cash from operations	243	253	320	231	240	265
Investing activities
Capital expenditures	−358	−391	−357	−248	−231	−206
Other investing cash flows	−410	26.8	22.4	−18.8	7.5	19.1
Cash from investing	−767	−364	−335	−267	−223	−187
Financing activities
Financing cash flow items	−1.3	−1.1	−2.8	−0.5	5.9	0.3
Cash dividends paid	−2.7	−48.0	−49.3	−40.8	−44.5	−46.9
Issuance (retirement) of debt, net	–	–	–	–	–	–
Other financing cash flows	529	227	96.1	87.4	47.7	−15.6
Cash from financing	525	178	43.9	46.0	9.1	−62.2
Foreign exchange effects	−13.4	−1.4	−3.4	4.7	2.4	−6.8
Net change in cash	−12.6	65.2	26.3	15.1	28.6	8.7
Free cash flow	−115	−138	−36.7	−16.8	9.6	58.6

Disclaimer

The financial data presented in this report is delayed and obtained from sources QDD Research believes to be reliable, including stock exchanges, SEDAR, and EDGAR. However, no representation or warranty is made as to the accuracy, completeness, or timeliness of the information. QDD Research accepts no liability for any errors, omissions, or financial losses arising from the use of this data.

This report is generated using a fully systematic and quantitative approach. All factor scores and the overall quant rating (ranging from D to A+) are derived from algorithmic models and are based solely on objective financial metrics. These scores are intended for informational purposes only and should not be interpreted as investment advice or a recommendation to buy, sell, or hold any securities.

QDD Research is not a registered investment advisor or broker-dealer and does not provide personalized financial advice. The content is not tailored to the specific investment goals, financial situation, or risk profile of any individual investor. We strongly encourage readers to consult with a licensed broker or investment advisor before making any investment decisions based on the information contained in this report.

Live quote provided by TradingView. Report data updated Nov 1, 2026 after market close.